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microenvironments and compartmental-
ized spaces. Inspired by nature, various 
approaches have been used to combine 
functional molecular units (natural or 
synthetic) with supramolecular assem-
blies to develop the first prototypes of 
artificial cells[1,2] with the aim of providing 
micrometer range compartments with 
cell-like properties for understanding 
fundamental biological phenomena and 
processes, and eventually offering solu-
tions to medical problems.[1–3] Various 
designs have been used to generate cell-
sized compartments with single specific 
functions[4–10] as a result of inserting func-
tional biomacromolecules (i.e., enzymes, 
membrane proteins) in a certain type of 
synthetic template, e.g. lipid- or polymer-
based giant unilamellar vesicles,[8,11–14] 
lipid-coated porous silica nanoparticles,[9] 
layer-by-layer capsules,[10] membrane free 
microdroplets,[15] or micro-scale proteino-
somes.[5] However, these simple artificial 
cells with an intracompartment medium 
mainly based on buffer-solutions,[16] and 
only recently extended to bacterial cell 
extracts,[17,18] lack the multicompartment cell architecture and 
complexity of cytosolic cell media. A recent advance in the 
development of artificial cells has been achieved by constructing 
“compartments-in-compartment” microscale structures that are 
based on encapsulation of nanoscale liposomes/polymersomes 
inside polymer-/lipid-based giant unilamellar vesicles with 
sizes in the micrometer range.[13,19] Multicompartmentalization 
allows biomacromolecules placed in different compartments to 
take part in two/three step cascade reactions.[13,20,21] However, 
the use of simple buffers as internal media inside the compart-
ments, and of organic solvents or emulsions during the prepa-
ration procedures, which can affect the biomolecules, represent 
severe drawbacks of current multicompartment systems.
An elegant strategy to yield compartment systems with more 
complex composition is based on the generation of cell-derived 
giant plasma membrane vesicles (GPMVs).[22–24] The mem-
brane and internal composition directly mirror the composi-
tion of the cells from which they originated, except for larger 
cellular organelles and intracellular structures (e.g., nuclei, 
Golgi apparatus, vesicles).[25] Although this is very promising 
for situations requiring a complex composition of the inner 
cavity of the compartment, efforts to date have been mainly 
Despite huge need in the medical domain and significant development 
efforts, artificial cells to date have limited composition and functionality. 
Although some artificial cells have proven successful for producing thera-
peutics or performing in vitro specific reactions, they have not been inves-
tigated in vivo to determine whether they preserve their architecture and 
functionality while avoiding toxicity. Here, these limitations are overcome 
and customizable cell mimic is achieved—molecular factories (MFs)—by 
supplementing giant plasma membrane vesicles derived from donor cells 
with nanometer-sized artificial organelles (AOs). MFs inherit the donor cell’s 
natural cytoplasm and membrane, while the AOs house reactive components 
and provide cell-like architecture and functionality. It is demonstrated that 
reactions inside AOs take place in a close-to-nature environment due to the 
unprecedented level of complexity in the composition of the MFs. It is further 
demonstrated that in a zebrafish vertebrate animal model, these cell mimics 
show no apparent toxicity and retain their integrity and function. The unique 
advantages of highly varied composition, multicompartmentalized architec-
ture, and preserved functionality in vivo open new biological avenues ranging 
from the study of biorelevant processes in robust cell-like environments to 
the production of specific bioactive compounds.
© 2020 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, 
Weinheim. This is an open access article under the terms of the Creative 
Commons Attribution License, which permits use, distribution and repro-
duction in any medium, provided the original work is properly cited.
1. Introduction
Life is based on an incredibly complex scenario in which 
biochemical reactions take place in specifically defined 
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devoted to their supplementation with small molecular weight 
compounds, or with biomolecules, such as lipids, or pro-
teins,[26] and only one study has involved the internal encapsu-
lation of nanoparticles.[27] There are currently no reports of the 
creation of functional artificial cells with the outer membrane 
complexity of a cell, and an internal cytoplasm.
Here, we introduce a general strategy for creating micro-
scale bioinspired molecular factories (MFs) by supplementing 
GPMVs with the necessary molecules and nanocompartments 
serving as artificial organelles (AOs) in order to mimic the archi-
tecture and functionality of eukaryotic cells, and then evaluate 
their performance in vivo. AOs are formed by encapsulation of 
enzymes inside polymersomes equipped with channel porines, 
prior to their internalization by donor cells. AOs have various 
advantages, such as an increase in the in situ enzymatic activity 
by nanoscale confinement, a protection of the enzymes inside 
their cavity and the possibility to obtain separate reaction 
spaces by coencapsulation of different AOs when more com-
plex reactions are studied.[28–30] In our approach, donor cells are 
first preloaded with supplementary cargos (synthetic molecules, 
nanocompartments and AOs) and simultaneously engineered 
(genetically if necessary) to overexpress specific biomacromole-
cules. Then a special “vesicular buffer” is added to the cells and 
induces formation of GPMVs that are equipped with the func-
tional artificial cargoes, specifically implemented by prior inter-
nalization into the donor cells (E-GPMVs). The hosting by AOs 
of reactive components, which perform desired reactions, rep-
resent the key elements for inducing specific biofunctionality 
of the MF as they can diffuse and function in situ (Figure 1). 
Together, the intrinsic composition of GPMVs with the same 
membrane and cytosol environment as the donor cells and the 
addition of functional AOs induce an unprecedented complexity 
of the resulting MFs that supports production of desired com-
pounds/signals in a close-to-nature manner. We have assessed 
these MFs in vivo to study whether they preserve their archi-
tecture and functionality, and thus serve as cell-mimics. As an 
example of a medical application we engineered MFs to support 
in situ the enzymatic degradation of H2O2, which is well known 
to be involved in oxidative stress, and plays a significant role 
in many disease states including arthritis, Parkinson’s disease, 
cancer, and AIDS. As these MFs closely represent cell mimics, 
they are expected to serve as the basis for developing highly effi-
cient therapeutic and diagnostic solutions for which there is a 
tremendous need to decrease global medical costs.
2. Strategy to Create MFs with Architecture 
and Functionality as Cell Mimics
Achievement of a close-to-nature cell mimic requires the 
transfer of functional elements (confined AOs, synthetic- and 
biomolecules) necessary to support overall functionality inside 
GPMVs used as micrometer sized compartments with intrinsic 
natural composition.[2] At the same time, the resulting hybrid 
cell-derived compartment should simultaneously be stable 
and allow exchange of molecules with the environment as in a 
natural cell.[31] First we produce AOs by a bottom-up approach 
in which we equip synthetic nanocompartments (polymer-
somes) with active compounds (enzymes, proteins, mimics), 
and simultaneously insert membrane proteins to allow in 
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Figure 1. Strategy for creating bioinspired molecular factories. To create a molecular factory (MF) we start by internalizing artificial cargoes (specific 
molecules and preformed artificial organelles based on polymersomes loaded with active compounds) in the donor mammalian cell. The membrane of 
the donor cell can also be modified to contain proteins or receptors of interest. Once loaded with all the necessary components of the MF, a transfer 
of material from the donor cell cytoplasm and membrane is achieved during vesicle formation. After isolation, the MFs are completely independent 
of the donor cells.
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situ catalytic reactions.[29] Then we introduce the necessary 
elements in a human-derived model cell line, i.e., HepG2 
liver carcinoma, by genetic overexpression (e.g., enzymes, 
proteins) and internalization (e.g., nanocompartments, AOs). 
After internalization of the nanocompartments and/or artifi-
cial organelles, we add a mixture based on a combination of 
molecules in order to induce the GPMV formation (“vesicula-
tion buffer”). The vesiculation buffer induces a direct budding 
of the cellular plasma membrane, during which, freely dif-
fusing entities present in the cellular cytosol are transferred to 
the formed GPMV.[22] 4–5 h after, the newly equipped-GPMVs 
(E-GPMVs), containing cytosol supplemented with the artifi-
cial cargoes, are separated from cell debris by centrifugation 
and then isolated. The components of the vesiculation buffer 
are not expected to show toxicity in vivo after E-GPMV forma-
tion, due to their relatively low half-life.[32] In order to establish 
the size distribution of E-GPMVs, we supplement them with 
a fluorescent model membrane protein LcK tyrosine kinase-
GFP (Lck-GFP) by genetically engineering HepG2 cells to 
overexpress this protein using a baculovirus gene transfer 
(BacMam 2.0).[33] When Lck-GFP is successfully inserted, it pre-
serves its fluorescence property, and does not affect the integrity 
of the membrane compartment (Figure S1, Supporting Infor-
mation), in agreement with previous reports about the inser-
tion of gap junction proteins in the membrane of giant plasma 
membrane vesicles.[26,34,35] E-GPMVs are isolated with a size 
range of 2–20 µm, as demonstrated by confocal laser scanning 
microscopy (CLSM) and flow cytometry data (Figure 2A–C). 
Distribution of the resulting E-GPMV sizes is lognormal with 
the probability density function: mean 8.84 µm and standard 
deviation 0.47 µm (p-value = 0.996 according to Kolmogorov–
Smirnov test) (Figure S2, Supporting Information).
3. E-GPMVs with Simultaneously Modified 
Membranes and Cavities
We first tested whether our approach allows supplementing 
E-GPMVs with synthetic molecules to improve the mechanical 
stability of their membranes, a necessary step for overcoming 
the limited intrinsic stability of giant plasma membrane 
vesicles. As model compounds for this purpose, we selected a 
synthetic polymer, cholesterol-functionalized polyethylene glycol 
(PEG) 5000 fluorescein isothiocyanate (Chol-PEG5000-FITC, 
5000 g mol−1), which anchors its hydrophobic region in the 
membranes whilst protecting the membrane surface through 
steric shielding of the PEG chains (Figure 2A,D).[36] Successful 
anchoring of Chol-PEG5000-FITC in HepG2 membranes and its 
transfer to the E-GPMV membranes was identified by the FITC 
signal associated with the membrane in CLSM (Figure 2A), and 
further confirmed by flow cytometry analysis (Figure 2D).
To clarify whether phosphatydilserine was accessible on 
the outer interface of the membrane, we compared E-GPMVs 
with and without modification with Chol-PEG5000 after 
staining with Annexin V, a well-known reporter for phospha-
tydilserine. Indeed, Chol-PEG5000 was capable of partially 
shielding the binding of Annexin V (34 kDa) to the outer 
interface of the plasma membrane (Figure 2E). In addition, 
HepG2 derived GPMVs expressed specific HepG2 membrane 
markers, such as the liver specific asialoglycoprotein receptor 
(Figure S3, Supporting Information). Insertion of polymer 
chains in the membrane of E-GPMVs makes the membrane 
protein-repellent (as is the case with PEG), and increases its 
stability, as in lipid membranes. The sizes determined by 
CLSM of E-GPMV-equipped with Chol-PEG5000 were fitted 
with a lognormal function with a probability density function 
mean of 8.92 µm and standard deviation 0.50 µm (p-value 
= 0.08 according to Kolmogorov–Smirnov test) (Figure S4, 
Supporting Information) and complemented by flow cytom-
etry (Figure S5, Supporting Information). E-GPMVs with 
Chol-PEG5000 inserted in their membranes have a larger size 
range than GPMVs without the polymer (Figure 2F), but the 
difference of the mean values is not statistically significant 
(p-value = 0.001, Welch two sample t-test and p-value = 0.005, 
Wilcoxon rank sum test).
In order to obtain E-GPMVs with a modified membrane and 
inner cavity, we simultaneously equipped them with a small 
hydrophilic fluorophore (CellTracker Deep Red Dye, referred 
herein as CTDR)[37] and Chol-PEG5000-FITC polymer. First, the 
fluorescence intensity associated with CTDR alone indicates its 
successful transfer to the inside of the E-GPMVs in a concen-
tration dependent manner, in the range 1 × 10−6 to 10 × 10−6 m 
(Figure S6, Supporting Information), and is in agreement with 
the previously reported transfer of low molecular weight com-
pounds present in the cytoplasm of the donor cells.[26] However, 
we observed that this process is not linear, but exponential, and 
thus by controlling the number of desired molecules in the 
donor cell cytosol, it is possible to control their final amount 
inside E-GPMVs, which is a necessary step when reactions have 
to be implemented inside MFs. Second, when CTDR and the 
polymer were transferred, it was shown by flow cytometry that 
more than 90% of the derived compartments presented fluo-
rescence signals associated with both the CTDR fluorophore 
and the Chol-PEG5000-FITC polymer molecules (Figure S7, 
Supporting Information). In addition, flow cytometry analysis 
indicated an increase in membrane stability of the compart-
ments simultaneously equipped with Chol-PEG5000 and CTDR 
(Figure S5C, Supporting Information) in agreement with the 
observation for PEGylated lipid vesicles.[38] Similarly, CDTR 
and the membrane protein Lck-GFP were successfully cotrans-
ferred to E-GPMVs and were located inside the cavity and in the 
membrane, respectively: our approach allows specific localiza-
tion of the artificial cargos required to support the molecular 
machinery (Figure S6A, Supporting Information). A necessary 
step for the feasibility of our strategy to create MFs was to spe-
cifically colocalize biomolecules inside GPMVs to further sup-
port their internal reactions/functionality. HepG2 cells were 
treated to overexpress hydrophilic enhanced green fluorescent 
protein (e-GFP), a combination of hydrophilic molecules, red 
fluorescent protein (RFP) and eGFP (RFP/eGFP), and a com-
bination of hydrophilic Actin-RFP and hydrophobic Lck-GFP 
(Actin-RFP/Lck-GFP).
The fluorescence signals arising from the compartment 
cavity or membrane provided an evaluation of the presence 
of the biomacromolecules (Mw > 30 kDa) by CLSM micro-
graphs (Figure 2A; Figure S8, Supporting Information). Both 
the hydrophilic eGFP, and when added in combination with a 
second hydrophilic protein, RFP, were successfully transferred 
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to cavities of the E-GPMVs (Figure S8, Supporting Information). 
Colocalization correlation coefficients for E-GPMVs loaded 
with hydrophilic biomolecules eGFP and RFP (PCC = 0.85 
± 0.11, M1 = 0.86 ± 0.21, and M2 = 0.78 ± 0.1) indicate that 
the proteins were simultaneously transferred and specifically 
localized in the cavity (Figure S8B, Supporting Information). 
Similarly, a combination of hydrophilic and hydrophobic pro-
teins (Actin-FRP and Lck-GFP, respectively) was transferred to 
the appropriate locations inside E-GPMVs, the cavity and the 
membrane, respectively (Figure 2A).
4. E-GPMVs with Cell-Specific 
Subcompartmentalized Architecture
In order to design a multicompartment system equivalent 
to eukaryotic cells, we envisioned the transfer of nanosized 
vesicular subcompartments (liposomes and polymersomes) 
to equipped-GPMVs, during the passive flow of cytoplasm 
that gradually fills the blebbing plasma membrane that forms 
a GPMV. This represents a challenging step because of the 
need to preserve the integrity of both nano-compartments 
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Figure 2. Transfer of cytosolic components from the cellular cytosol into E-GPMVs. A) Left column: Top) Schematic representation of HepG2 cells 
with enhanced membrane and cytosolic content. Central) Illustration of the formation of equipped-GPMV (E-GPMV) from the donor cells. Bottom) 
Isolated E-GPMV. Middle column: Top) CLSM micrograph of HepG2 cells containing Chol-PEG5000-FITC copolymer in the membrane (Green), Scale 
bar = 15 µm. Central) CLSM micrograph of E-GPMVs formation by several cells, Scale bar = 40 µm; Chol-PEG5000-FITC copolymer is inserted both in 
the cells and in the GPMVs membrane. Bottom) CLSM micrograph with a zoom of one isolated E-GPMV containing Chol-PEG5000-FITC copolymer 
in the membrane (Scale bar = 10 µm). Right column: Top) CLSM micrograph of HepG2 cells simultaneously containing Actin-RFP protein (Red) and 
the membrane protein Lck-GFP (Green), Scale bar = 15 µm. Central) CLSM micrograph of E-GPMVs formation by several cells, Scale bar = 40 µm; 
Actin-RFP protein (Red) and the membrane protein Lck-GFP (Green) are located both in the cells and in the GPMVs. Bottom) CLSM micrograph with 
a zoom of one isolated E-GPMV containing Actin-RFP protein (Red) and the membrane protein Lck-GFP (Green), Scale bar 10 µm. CLSM Controls are 
available in the Supporting Information. B) Flow Cytometry analysis of E-GPMVs, size characterization by sideward and forward scattering analysis. 
The ellipse represents E-GPMV populations (2.0–9.9 µm) used for analysis by flow cytometry. Blue to red color-coded polystyrene particles in sizes 
from 2.0, 3.4, 5.11, 7.6, 9.9, and 14.3 µm. Green: E-GPMV population. C) Size distribution of the E-GPMVs with membranes supplemented with the 
membrane protein Lck-GFP obtained by analysis of CLSM micrographs. N = 501 individual E-GPMVs. D) Flow cytometry analysis of E-GPMVs equipped 
with Chol-PEG5000-FITC copolymer (Green) and control (unmodified) GPMVs (Gray). E) Flow cytometry analysis of Annexin V-Atto488 binding to 
E-GPMVs equipped with the copolymer Chol-PEG5000: Control GPMVs without Annexin V (Red), control GPMVs with added Annexin V (Green) and 
E-GPMVs equipped with Chol-PEG5000 copolymer and added Annexin V (Orange). F) Size distribution of E-GPMVs equipped with Chol-PEG5000-FITC 
copolymer obtained by analysis of CLSM micrographs. N = 501 individual E-GPMVs.
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and GPMVs. First, we prepared 100–200 nm model liposomes 
based on DSPC:chol:DSPE-PEG (48:42:10 mol%) and 
DSPS:chol:DSPE-PEG (53:42:5 mol%) by the lipid film rehydra-
tion technique and subsequent size adjustment by extrusion. 
Neutral (DSPC) and negatively charged (DSPS) phospholipids 
selected to form liposome membranes were enhanced with 
PEGylated phospholipids (DSPE-PEG) to increase steric repul-
sion. This subsequently reduced the expected liposome–GPMV 
membrane interactions, thereby supporting free movement 
and preservation of the liposome integrity once in the GPMV 
cavity. In addition, PEGylated phospholipids (DSPE-PEG) are 
expected to increase the fraction of the cell-integrated liposomes 
escaping the endosome/lysosome.[39] A 1 × 10−3 m sulforho-
damine B (SRB) solution in phosphate-buffer saline pH 7.4 
(PBS) was used during the film rehydration method, resulting 
in encapsulation of the fluorescent tracker in the liposome 
cavity. The encapsulated SRB served as a marker for investi-
gating both the integrity of the liposomes and their dynamics 
inside the GPMVs. After removing nonencapsulated free SRB 
from prepared SRB-loaded liposomes by size-exclusion chro-
matography, the liposomes were characterized by dynamic 
light scattering (DLS) and transmission electron microscopy 
(TEM) (Figure S9, Supporting Information). Vesicular struc-
tures were obtained with a hydrodynamic diameter (DH) 
of 173.9 ± 9.0 nm (DSPS-based liposomes) and DH of 100.8 
± 1.7 nm (DSPC-based liposomes) and PDIs of 0.197 ± 0.01 
and 0.05 ± 0.01, respectively. Liposomes based on DSPC had 
a neutral surface charge (ζ = 0.507 ± 0.1 mV), whereas those 
based on DSPS were slightly negatively charged (ζ = −3.5 ± 0.5 
mV). Encapsulation of SRB inside the liposome cavity and suc-
cessful removal of the nonencapsulated dye were demonstrated 
by fluorescence correlation spectroscopy (FCS): the free SRB in 
solution after purification was 4.3% for DSPS-based liposomes 
and 0.6% for DSPC-based liposomes (Figure S9, Supporting 
Information).
Cellular internalization of liposomes was achieved by incu-
bating HepG2 cells treated to overexpress LcK-GFP in the pres-
ence of both types of liposome at a total lipid concentration of 
20 × 10−3 m for 24 h. It is noted that PEG does not significantly 
hinder the unspecific, passive endo- or pinocytotic concentra-
tion dependent uptake of these stealth liposomes after 24 h.[39] 
The HepG2 cells were then extensively washed with culture 
medium to remove all nonintegrated liposomes. After the 
vesiculation process of the donor cells, we observed by CLSM 
micrographs that there was little to no diffuse SRB signal 
present in the GPMVs (Figure S10, Supporting Information). 
On contrary, distinct localized fluorescence signal spots corre-
sponding to the SRB-loaded liposomes were observed, with a 
completely different aspect than the diffuse fluorescence signal 
of the low molecular weight fluorophore CDTR (control), which 
was homogeneously distributed throughout the GPMV cavity 
(Movies S1 and S2, Supporting Information). The distinct flu-
orescent spots associated with the liposomes indicate that the 
transfer process did not affect the integrity of the liposomes 
inside equipped-GPMVs.
In order to improve the stability of the nanocompartments 
inside equipped-GPMVs, we used polymeric vesicles (poly-
mersomes) that are known to have higher mechanical sta-
bility than liposomes due to their thicker membranes.[40,41] 
First, polymersomes based on the amphiphilic poly(2-
methyloxazoline)-block-poly(dimethylsiloxane)-block-poly(2-
methyloxasoline) (PMOXA6-PDMS44-PMOXA6) copolymer 
were formed using the thin film rehydration method, since this 
type of polymersome has already been used for the develop-
ment of catalytic compartments,[42] and even AOs by encapsula-
tion of enzymes and proteins.[29,43] We encapsulated fluorescent 
SRB or carboxyfluorescein (CF) inside polymersome cavities to 
serve as reporters for the polymersome spherical architecture 
and membrane integrity. Architecture and size of assemblies 
were determined by a combination of transmission TEM, Cryo-
TEM, DLS, and FCS (Figure 3; Figure S11, Supporting Informa-
tion). Polymersomes with DH of 187 ± 13 nm, and a net neutral 
Zeta potential (ζ = −0.15 ± 1.77 mV) were obtained. Successful 
encapsulation of the fluorescent dye within the polymersomes 
and purification from nonencapsulated dye, were determined 
by FCS (free SRB fraction: 10.7%).
PMOXA-PDMS-PMOXA polymersomes have been previ-
ously reported as cyto-compatible and capable of successful 
escape from endosomes with preserved integrity.[44] Therefore, 
HepG2 cells were treated to overexpress LcK-GFP and cultured 
in the presence of 1 mg mL−1 PMOXA6-PDMS44-PMOXA6 
polymersome solution to promote their up-take.[29,41] Uptake 
of SRB-loaded polymersomes into HepG2 cells prior to the 
vesiculation process, and their subsequent transfer from the cel-
lular cytoplasm into E-GPMV cavities was evaluated by CLSM 
(Figures 3A and 4; Figure S12G–I, Supporting Information). 
Whilst LcK-GFP was inserted in the E-GPMV membrane, 
the polymersomes were encapsulated inside the E-GPMVs 
cavity (Figure 4A–C), and their architecture was preserved 
even after storage at 20 °C for 7 days (Figure S12, Supporting 
Information). Distinctly localized fluorescence spots associ-
ated with the SRB-loaded polymersomes within the E-GPMV 
cavity, with negligible fluorescence spreading, were observed 
by CLSM. The long-term stability of polymersomes inside 
E-GPMVs (7 days) supports creation of a robust multicompart-
ment cell-like architecture. In addition to CLSM, transmission 
electron microscopy analysis of E-GPMVs revealed polymer-
some-like structures within ruptured E-GPMVs (Figure S13, 
Supporting Information). The escape of polymersomes from 
the endosomes and their preserved architecture inside the 
isolated E-GPMVs were facilitated by the change in the intra-
cellular membrane structures (i.e., lysosomal, endosomal, 
organelles) induced during E-GPMV formation. Indeed, upon 
incubating the cells for 1 min with Chol-PEG-Cy5, the fluoro-
phore rapidly accumulated in the intracellular membrane struc-
tures (Figure S14A, Supporting Information), and dissipation 
of the fluorescence signal of Chol-PEG-Cy5 upon vesiculation 
(Figure S14B, Supporting Information) suggests that E-GPMV 
formation induces changes in intracellular membranes, which 
thus facilitate escape of polymersomes.
Interestingly, unlike PEG shielded liposomes, which moved 
freely inside E-GPMVs cavity, polymersomes moved along 
the membrane, which might indicate a slight interaction 
with the inner interface of the GPMV membrane (Figure 4; 
Figure S12B,C, Figure S15, and Movie S3–S7, Supporting Infor-
mation). This behavior has been observed immediately after the 
polymersomes transfer to the cavity of the GPMVs, while these 
later were still attached to the donor cells (Movies S4 and S7, 
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www.advancedsciencenews.com
1901923 (6 of 13) © 2020 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.advancedscience.com
Supporting Information). However, their rapid movement at 
the membrane-cavity interface indicates that this interaction 
is minor and does not affect their mobility. Besides, polymer-
somes did not escape from the cavity of E-GPMVs as indicated 
by the maximum intensity projection images of Z stacks of 
CLSM micrographs (Figure 4B). 3D reconstruction of the Z 
stacks of these CLSM micrographs indicates that there was an 
efficient transfer of polymersomes into E-GPMVs. Furthermore, 
this was concentration dependent as observed by incubating 
HepG2 cells in the presence of increasing polymersome con-
centrations in the range 0.5–3 mg mL−1 (Figure S16, Movie S7, 
Supporting Information). The number of polymersomes/E-
GPMV is described by a geometrical discrete distribution 
(Figure S17A, Supporting Information). The average number 
of polymersomes/E-GPMVs obtained in single plane pro-
jections of CLSM micrographs as function of the E-GPMVs 
size was statistically analyzed by ordinary least square fitting 
(OLS) (Figure S17B, Supporting Information). The best fit was 
obtained with a log–log formula (Supporting Information): 
ln (Nparticle) =  a ln(Sizeparticle) + b Sizeparticle with parameters 
a = 1.673 and b = −0.142 (adjusted R-squared = 0.9872). By 
increasing the initial concentration of polymersomes to be up-
taken by the donor cells from 0.5 to 3 mg mL−1, the percentage 
of polymersome-loaded E-GPMVs increased from 25%, to 89%. 
Each cell loaded with an initial polymersomes concentration 
of 0.5 mg mL−1 yielded 1.5 ± 5 E-GPMVs, whereas 3.6 ± 1.3 
E-GPMVs were generated for an initial polymersome concen-
tration of 3 mg mL−1. When SRB-loaded polymersomes and 
CF-loaded polymersomes were cotransferred inside E-GPMVs, 
their fluorescence signal did not overlap. The increased loading 
of GPMVs with increasing initial polymersome concentration 
and cotransfer clearly indicate that the polymersomes preserved 
their integrity and thus opens the possibility of a multicompart-
ment system with different types of nanocompartments.
The integrity of polymersomes inside E-GPMVs, and the 
exclusion of autofluorescence was also assessed by FCS. Dif-
fusion times of free SRB-loaded polymersomes in GPMV for-
mation buffer (τd Q1 = 5209.2 µs, Median = 8445.7 µs) were 
compared to compartmentalized SRB-loaded polymersomes in 
GPMVs (τd: Q1 = 9648.5 µs, Median = 20994.8 µs) (Figure 3C,D). 
Median values are based on 60 individual measurements of 
SRB-loaded polymersomes within an E-GPMV and SRB loaded 
polymersomes free in solution (PBS, pH 7.4), respectively. 
The shift to longer diffusion times for polymersomes inside 
E-GPMVs cavity is expected, because of the higher viscosity of 
the cytosol compared to buffer conditions. The free SRB fraction 
in solution (after polymersome preparation and purification) 
and that within E-GPMVs were determined by FCS. We used a 
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Figure 3. Transfer of cytosolic components from the cellular cytosol into E-GPMVs. A) Left column: Top) Schematic representation of HepG2 cells with 
enhanced membrane and cytosolic content. Central) Illustration of the formation of several equipped-GPMV with multicompartment structure (E-GPMV) 
from the donor cells. Bottom) One isolated E-GPMV with microcompartment structure. Right column: Top) CLSM micrograph of HepG2 cells containing 
membrane protein LcK-GFP (Green) and SRB-loaded PMOXA6-PDMS44-PMOXA6 polymersomes (Red), Scale bar 20 µm. Central) CLSM micrograph 
of several E-GPMV, Scale bar 7 µm. Bottom) CLSM micrograph of one isolated E-GPMV simultaneously containing Lck-GFP protein and SRB-loaded 
PMOXA6-PDMS44-PMOXA6 polymersomes, Scale bar 5 µm. See Movies S3–S8 in the Supporting Information. CLSM Controls are available in the Sup-
porting Information. B) Cryogenic transmission electron micrograph of PMOXA6-PDMS44-PMOXA6 polymersomes in PBS pH 7.4. Scale bar represents 
200 nm (left) and 50 nm (right). C) FCS analysis of SRB-loaded PMOXA6-PDMS44-PMOXA6 polymersomes in PBS pH 7.4 (Blue) and SRB-loaded PMOXA6-
PDMS44-PMOXA6 polymersomes within E-GPMVs (Red), Free SRB at pH 7.4 PBS (Black). Arrowhead indicates the change in diffusion time from free 
SRB polymersomes once they are encapsulated in E-GPMVs. Dotted line—experimental auto correlation curves, full line—fit. Curves normalized to 1 to 
facilitate comparison. D) Frequency distribution of diffusion times taken from individual FCS measurements: SRB-loaded PMOXA6-PDMS44-PMOXA6 
polymersomes in PBS pH 7.4 (Blue) and SRB-loaded PMOXA6-PDMS44-PMOXA6 polymersomes within E-GPMVs (Red) (n = 67 and n = 30 respectively).
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two-component fit, where the diffusion time of the free SRB in 
solution (τd: Q1 = 24.4 µs Median = 27.2 µs) was fixed as the first 
component. Free SRB fractions were small both after polymer-
some purification and inside E-GPMVs (FractionSRB = 9.04% for 
polymersomes in E-GPMVs and 10.7% for free polymersomes) 
(Figures 3C,D, and 4). To further demonstrate the high degree 
of control of the inner composition of E-GPMVs, we transferred 
eGFP together with SRB-loaded PMOXA6-PDMS44-PMOXA6 
polymersomes into E-GPMVs. The separate localization of the 
fluorescence signals of SRB and eGFP indicates that individual 
subcompartments can exist within E-GPMVs with distinct 
nano-environments, which are different from the rest of the 
E-GPMVs (Figure 5A; Movie S8, Supporting Information). This 
strengthens our findings of a multicompartment architecture 
within E-GPMVs based on the values of the colocalization coef-
ficients (Figure 5A). For further applications, the variation of the 
number of polymersomes/E-GPMVs can be reduced by fluores-
cence activated cell sorting (FACS) of E-GPMVs.[45]
For the first time giant plasma membrane vesicles have 
been equipped with synthetic nanocompartments together with 
the desired biomolecules to generate subcompartimentalized 
architecture, which is characteristic of cells. The size of the 
encapsulated subcompartments can be modified prior to their 
up-take by the donor cells depending on the applications.
5. MF with Architecture and Functionality 
as Cell Mimics
To produce in situ AOs, we first preloaded polymersomes with 
specific biomolecules (enzymes, membrane proteins). We used 
AOs based on PMOXA6-PDMS44-PMOXA6 polymersomes 
Adv. Sci. 2020, 1901923
Figure 4. Subcompartmentalization within E-GPMVs. A) 3D reconstructions (left) and maximum intensity projection images of Z stacks (right) of 
E-GPMVs with multicompartment architecture. Top: SRB-loaded polymersomes inside E-GPMVs equipped with Lck-GFP. Red: signal of SRB-loaded 
polymersomes. Green: signal of Lck-GFP membrane protein. Bottom: SRB-loaded polymersomes and CF-loaded polymersomes inside E-GPMVs. 
Red: signal of SRB encapsulated inside polymersomes. Green: signal of CF encapsulated inside polymersomes. B) Single plane projections of different 
Z positions during E-GPMV Z-stacking process by CLSM. Z interval = 1 µm. Red: SRB loaded polymersomes. Green: Lck-GFP membrane protein. C) Single 
plane recordings of PMOXA6-PDMS44-PMOXA6 polymersomes inside E-GPMVs measured by CLSM. See Movies S3–S8 in the Supporting Information.
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combined with membrane proteins and enzymes, since they 
have already been reported to preserve their functionality in cells 
and in vivo.[29,43] Spatial localization of enzymes within AOs 
increases the enzyme-substrate affinity.[28] As a model we loaded 
horseradish peroxidase (HRP) into the cavities of PMOXA6-
PDMS44-PMOXA6 polymersomes that contained the bacterial 
outer membrane protein F (OmpF) in the membrane to control 
passage of specific substrates and products. We selected HRP 
because of its biological role in detoxification of H2O2, known 
as toxic by-products of mitochondrial respiration in eukaryotic 
cells, and its role in modulating the protein function of by thiol 
oxidation.[46,47] More recently, HRP has also gained significant 
interest in cancer research. Thus, its stability and bioversa-
tility have made HRP one of the most studied enzymes. Prior 
to incorporation, the purities of HRP and OmpF were deter-
mined by SDS-gel electrophoresis (Figure S18A, Supporting 
Information). OmpF was selected to render permeable the 
membrane of the polymersomes because, as a channel porin, 
it allows the diffusion of small hydrophilic molecules.[48] Previ-
ously inserted into the membrane of PMOXA-PDMS-PMOXA 
polymersomes, OmpF served as “gate” for an orientation inde-
pendent molecular flow.[42,49] HRP is able to convert H2O2, a 
well-known harmful compound involved in oxidative stress, and 
it will thus indicate whether our MFs could have efficient med-
ical applications. Both excess OmpF and nonencapsulated HRP 
are removed from the prepared AOs by dialysis. These AOs 
were characterized by DLS and TEM in terms of architecture 
and size (Figure 5A; Figure S18B–D, Supporting Informa-
tion). As expected, TEM micrographs show a typical deflated 
structure for the polymersomes because the measurements are 
carried out under vacuum. Enzyme encapsulation and mem-
brane protein insertion did not affect the self-assembly process, 
and resulted in polymersomes with a DH of 122 ± 1.6 nm. We 
used the formation of the fluorescent enzymatic resorufin-like 
product to characterize AOs in terms of functionality prior to 
their uptake by the donor cells (Figure 5A), and compared them 
with OmpF-deficient HRP-loaded polymersomes. It should be 
noted that OmpF permits diffusion of molecules with a mole-
cular cutoff of about 600 Da.[50]
In order to create a compartments-in-compartment archi-
tecture inside MFs, HepG2 cells were incubated with AOs 
(1 mg mL−1 polymer concentration) for 24 h to allow sufficient 
cellular uptake (Figure 5B,C). The distribution of the poly-
mersomes transfer to E-GPMV was observed to be concentra-
tion dependent. At an initial polymer concentration of 1 mg 
mL−1, E-GPMVs contained an average of 1.8 ± 1 polymersomes/
GPMV (Figure S16, Supporting Information). AOs based on 
encapsulation of HRP in similar conditions as we used here 
were reported to contain 6 ± 2 enzymes.[30] Therefore we cal-
culated that MFs encapsulated a range of 4–24 enzymes/MF. 
The relative fluorescence intensity of the resorufin-like product 
inside individual E-GPMVs when the encapsulated AOs were 
equipped with OmpF (Figure 5C), and when deficient of 
OmpF (Figure 5D), allowed the functionality of the MFs to 
be established. Amplex UltraRed was chosen as an enzymatic 
substrate to evaluate whether AOs preserved their function-
ality inside MF cavities because it can readily diffuse through 
their lipid membrane, but not through the polymersome 
membranes, unless they are equipped with OmpF pores.[29,51] 
Permeabilization of AOs by OmpF allowed the nonfluorescent 
substrate Amplex UltraRed to reach the encapsulated enzyme 
HRP within the cavity where it was converted to a fluorescent 
resorufin-like product in the presence of H2O2.[51] As the in situ 
enzymatic activity inside polymersomes was preserved in physi-
ological media, such as human serum,[30] the activity of AOs is 
not affected by their encapsulation inside E-GPMVs. Therefore, 
the reaction rate limiting step is no longer determined by enzy-
matic affinity, but by the diffusion of H2O2 through the lipid 
membrane of the MFs.[52–54] As the fluorescent resorufin-like 
product rapidly diffuses through the MF membrane into its 
environment, it is difficult to follow the reaction intercompart-
mentally. To circumvent this limitation for characterization 
purposes, we used photo-illumination to locally increase the 
amount of reactive oxygen species inside the MFs by irradiation 
with a λ = 543 nm laser after Amplex UltraRed accumulated 
inside the MFs.[55] Due to the reaction with H2O2, the conver-
sion of Amplex UltraRed to the resorufin-like product was 
visualized in presence of HRP, and a significant increase in 
the intensity of the fluorescence signal associated with the 
reaction product was observed for AOs inside MFs. Note that 
this increase in the concentration of the fluorescent product 
was expected due to the confinement of multiple AOs within 
GPMVs. As expected, the fluorescence within MFs subse-
quently decreased after ceasing irradiation (Movie S9, Sup-
porting Information). As expected, there is a difference in the 
fluorescence intensity inside the core of MFs due to the AOs 
degree of transfer, which is inducing as slight variation of the 
enzymatic substrate turnover. MFs loaded with polymersomes 
containing HRP but without OmpF and MFs loaded only with 
cytoplasm showed only a minor or no increase in fluorescence, 
because the reaction substrate did not diffuse through the poly-
mersome membranes without OmpF, and the reaction did not 
take place without the enzyme (auto-oxidation of substrate is 
only minor), respectively[51,55] (Figure 5; Figure S19, Movies S9 
and S10, Supporting Information). In addition, in the absence 
of AOs inside MFs, Amplex UltraRed was not converted into 
the fluorescent resorufin-like product (Figure 5; Figure S19, 
Supporting Information). Thus, we have demonstrated that a 
substrate able to diffuse through the membrane of E-GPMVs 
and inner AOs are necessary elements for MFs to be functional 
in a cell-like manner. As PMOXA-PDMS-PMOXA-based AOs 
have been previously reported to retain their activity for 7 days 
of storage and even preserve their integrity upon escape from 
endosomal and lysosomal compartments,[29,43,56] the only lim-
iting factor for the activity of MFs is the stability of the outer 
E-GPMV membrane. Reactions inside AOs freely moving in 
a complex medium, as in the cytoplasm of E-GPMVs, have 
neither previously been achieved in the field of giant plasma 
membrane vesicles, nor in that of artificial cells developed by 
bottom-up approaches.
6. In Vivo Evaluation of MF Functionality
Artificial cells that have previously been reported only showed 
functionality in vitro where they interacted with their environ-
ment, among themselves,[5] or with other eukaryotic/prokary-
otic cells[26] in culture or solid tumor models.[17] In order to 
Adv. Sci. 2020, 1901923
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Figure 5. Engineering a MF. A) Left: TEM micrograph of AOs based on PMOXA6-PDMS44-PMOXA6 polymersomes loaded with horseradish peroxidase 
(HRP) and equipped with OmpF. Scale bar: 500 nm. Right: Amplex UltraRed conversion kinetics of AOs equipped with OmpF (red) and AOs without 
OmpF (blue). Standard deviations are based on 3 individual measurements. B) Spatial colocalization in E-GPMVs. Left: Schematic representation 
of E-GPMVs containing SRB-loaded polymersomes and cytosolic GFP protein. Middle: CLSM micrograph of E-GPMVs containing SRB-loaded 
polymersomes (Red signal) and cytosolic GFP protein (Green signal). Right: Colocalization analysis of SRB-loaded polymersomes and GFP protein 
within E-GPMVs. PCC = 0.16 ± 0.14, M1 = 0.35 ± 0.1, M2 = 0.09 ± 0.09. n = 5 independent CLSM images. C) Functional MFs containing AOs, which 
convert in situ Amplex UltraRed into resorufin-like product. Left: Schematic representation of MFs containing AOs. Middle: CLSM micrograph of 
real-time production of the resorufin-like product by AOs inside MFs (Red signal). Right: Relative fluorescence intensity recordings of individual MFs 
equipped with AOs. See Movie S9, Panel (D) in the Supporting Information) Control MFs equipped with AOs with no OmpF. Left: Schematic repre-
sentation of E-GPMVs containing AOs without OmpF. Middle: CLSM Micrograph demonstrating the absence of conversion of Amplex UltraRed into 
the resorufin-like product when AOs inside MFs have no OmpF. Right: Relative fluorescence intensity recordings of individual MFs loaded with AOs 
without OmpF; See Movie S10 in the Supporting Information.
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study whether our MFs preserve their integrity and functionality 
and are nontoxic when injected in vivo, we selected zebrafish 
embryos (ZFEs) as a vertebrate animal model, which has pre-
viously been used to bridge the gap between in vitro studies 
and studies in mammalian organisms (e.g., rodents).[57] Due 
to their high optical transparency and relatively straightforward 
genetic modification (e.g., fluorescent tagging of immune cells 
or vasculature), ZFEs serve as appropriate models to determine 
the in vivo behavior of drugs and nanoparticles,[58,59] to serve 
as disease models,[60] and have recently also been used to visu-
alize the in vivo functionality of AOs.[29] In order to promote 
the stability of MFs in vivo and to decrease nonspecific pro-
tein adsorption, we supplemented the membrane with either a 
nonfluorescent or fluorescent derivative of cholesterol-polyeth-
ylene glycol-5000 as described above (Figure 2). In addition, we 
loaded their inner cavity with a fluorescent dye, CTDR, or water-
soluble proteins RFP, as markers for the hollow sphere nature 
of the E-GPMVs. The exact number of E-GPMVs injected could 
neither be fixed nor determined, due to the sedimentation pro-
cess when E-GPMVs were aspirated into the microinjection 
needle and subsequent needle fixation in the micro injector 
(10–15 min). As both GPMVs and PMOXA-PDMS-PMOXA 
polymersomes have been reported as noncytotoxic,[26,29] we 
did not expect toxic effects for their combination as E-GPMVs 
or MFs. Indeed, we did not observe acute toxicity, change of 
behavior, or heart failure in the injected ZFE. Further, for up to 
24 h post injection of E-GPMVs, no malformations, denatura-
tion of tissue fluids or the yolk mass were observed in the ZFE 
(Figure 6A). Follow up studies estimating the long-term survival 
rate of injected ZFE will serve to complete possible toxic effects 
of E-GMPVs, but they are beyond the scope of this article. Once 
injected, the process of the distribution of E-GPMVs in the vas-
culature of the organism started. E-GPMVs with sizes ranging 
from 2 to 10 µm were observed to be deposited in the endothe-
lium, or circulating in the vasculature of ZFE for up to 8 h 
(Figure 6B–F; Movies S11 and S12, Supporting Information). 
Astonishingly, the membrane of individual MFs was sufficiently 
robust to survive the aspiration/injection procedure, and the 
presence of shear stress during blood circulation. The hollow 
sphere architecture of the MFs, and the preservation of its AOs 
were evaluated by CLMS analysis, and photo bleaching of RFP 
within the MF cavities, where there was a typical exponential 
photo bleaching behavior, as compared to ZFE melanocytes[61,62] 
(Figure 6B,C; Figure S20, Supporting Information).
To test the functionality of our cell-like MFs in a living ver-
tebrate model, MFs were injected into the peritoneal cavity 
(PC) of transgenic zebrafish with green fluorescent vasculature 
(kdrl:EGFP zebrafish) 4 days post fertilization. The nonvascular 
injection site was chosen to achieve a better control over the overall 
reaction process, and to avoid background fluorescence from the 
reaction of H2O2 and Amplex UltraRed substrate with ZFE eryth-
rocytes in blood circulation.[29] Prior to the injection of MFs, we 
injected CTDR loaded PEG equipped GPMVs into the perito-
neal space of ZFE in order to evaluate their stability (Figure S21, 
Supporting Information). At 6 h post injection individual 
E-GPMVs with CTDR were observed inside their cavities. 
Based on the stability and overall distribution of E-GPMVs in 
the peritoneal space of ZFE (Figure S21, Supporting Informa-
tion), the functionality of MFs injected into the peritoneal space 
was investigated in the same area at a higher zoom. MFs were 
preincubated with H2O2 and the reaction substrate for 2 h in 
order to provide the required reaction substrates. After their intra-
peritoneal injection into ZFE, a second addition of the reaction 
substrate and H2O2 was performed directly prior to injection 
into ZFE, to increase the in vivo substrate levels: a direct visu-
alization of the reaction inside injected MFs is thus possible. The 
ZFE peritoneal space was observed by CLSM micrographs, which 
indicated an increase in the signal associated with the resorufin-
like product inside injected MFs, whereas the signal of substrates 
injected in ZFEs without MFs remained at the background level 
(Figures S22,23, Supporting Information). A statistically signifi-
cant 81 ± 37% increase in fluorescence compared to the back-
ground was observed within MFs if AOs were equipped with 
OmpF as compared to an 8 ± 5% increase when OmpF was 
absent (Figure 6G,H; Figure S18, Supporting Information). Statis-
tical significance was determined by the Student’s t-test. While we 
tested the in vivo functionality directly after injection within a 2 h 
timespan, due to limitations of the animal permission the experi-
ment had to be stopped. We expect that MFs are able to function 
in vivo for longer periods of time because the substrate of the 
enzymatic reaction inside AOs is present in the bioenvironment 
of MFs, and they were still intact 8 h post injection (Figure 6B–F). 
Overall, these unprecedented findings show the usefulness of our 
MFs with complex composition as artificial cell mimics in vivo.
7. Conclusions
We have introduced customizable MFs as cell mimics that have 
a natural membrane and cytosol interior combined with AOs 
that produce desired molecules or signals. Preformed poly-
mersomes taken up by the donor cells are transferred into 
hybrid giant plasma membrane vesicles, E-GPMVs, where they 
preserve their integrity and move along the membrane to give 
a multicompartment cell-like architecture; membrane stability 
of the E-GPMVs is improved by insertion of polymers. In addi-
tion, polymersomes loaded with catalytic compounds, such as 
enzymes, play the role of AOs and support in situ reactions 
inside MFs. Compared to previously reported artificial cells 
based on bottom-up approaches, our MFs represent an advance 
in terms of complexity (given by the intrinsic composition of 
GPMVs supplemented by nano-objects transfer) and function-
ality (supported by in situ enzymatic reactions inside AOs) 
that has been proven in vivo. Such MFs open new avenues for 
understanding bioreactions and functions in a close-to-nature 
environment. In addition, by systematic optimization of the 
conditions in which MFs are produced, it is possible to control 
the amount of synthetic cargoes with which these artificial cells 
are equipped. This control can be used to favor a specific inter-
action, reinforce stability, or tune the overall efficiency of the 
reactions inside the AOs, as an essential step towards medical 
applications. Further, our experiments with ZFEs show that 
these MFs are nontoxic, and can successfully persist in vivo 
while retaining their integrity and functionality. Such MFs are 
developed in a straightforward manner that can be easily scaled-
up, and thus have potential for development of highly efficient 
in vitro diagnostic and in vivo therapeutic solutions depending 
on the specificity of the enzymes loaded inside the AOs.
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Figure 6. MF functionality in vivo. A) Schematic representation of ZFE injection and imaging. Green: ZFE vasculature. B) RFP-loaded, Chol-PEG500 
enhanced MFs in ZFE circulation. Red: RFP in MF cavity. C) RFP-loaded Chol-PEG5000-MFs (Red) deposited on ZFE vasculature (Green). D) Decay in 
fluorescence intensity of individual MFs, in ZFE during photo bleaching. Red: RFP signal. Black: Melanocyte signal. E1) CLSM micrograph before photo 
bleaching. E2) CLSM micrograph after photo bleaching. F) CLSM micrographs of CTDR and Chol-PEG5000-FITC MFs deposited in ZFE vasculature. 
Blue: CTRD signal, Green: Chol-PEG5000-FITC signal. See Movies S11–S14 in the Supporting Information. G) In vivo functionality of MFs in ZFE. 
Red: Resorufin-like product signal. Green: Chol-PEG5000-FITC signal. H) Production of resorufin-like product by MFs in ZFE. Relative fluorescence 
intensity increase within an individual MF (single confocal plane) as compared to background fluorescence. Control: Individual MF containing AOs 
with no OmpF.
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